دورية أكاديمية
Impact of Canagliflozin in Patients with Type 2 Diabetes after Hospitalization for Acute Heart Failure: A Cohort Study.
| العنوان: | Impact of Canagliflozin in Patients with Type 2 Diabetes after Hospitalization for Acute Heart Failure: A Cohort Study. |
|---|---|
| المؤلفون: | Martín, Ernesto, López-Aguilera, José, González-Manzanares, Rafael, Anguita, Manuel, Gutiérrez, Guillermo, Luque, Aurora, Paredes, Nick, Oneto, Jesús, Perea, Jorge, Castillo, Juan Carlos |
| سنة النشر: | 2021 |
| المجموعة: | Sistema Sanitario Público de Andalucía (SSPA): Repositorio |
| مصطلحات موضوعية: | N-terminal pro-B-type natriuretic peptide, canagliflozin, heart failure, readmissions, sodium glucose co-transporter 2 inhibitor |
| الوصف: | Heart failure (HF) is one of the mayor contributors to cardiovascular morbidity and mortality in patients with diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated to reduce the risk of hospitalization for HF in patients with type 2 diabetes mellitus (T2D). We aimed to assess the risk for re-hospitalization in a cohort of patients hospitalized for HF according to whether or not they received canagliflozin at discharge, as well as changes in N-terminal pro-B-type natriuretic peptide (NT-ProBNP) concentration during follow-up. We conducted a retrospective longitudinal study at a tertiary centre including 102 consecutive T2D patients discharged for acute HF without contraindication for SGLT2 inhibitors. We compared adverse clinical events (HF rehospitalization and cardiovascular death) and NT-ProBNP changes according to canagliflozin prescription at discharge. Among the 102 patients included, 45 patients (44.1%) were prescribed canagliflozin and the remaining 57 (55.9%) were not prescribed any SGLT2 inhibitors (control group). After a median follow-up of 22 months, 45 patients (44.1%) were hospitalized for HF. Most of the rehospitalizations occurred during the first year (37.3%). HF readmission at first year occurred in 10 patients (22.2%) in the canagliflozin group and 29 patients (49.1%) in the control group (hazard ratio (HR): 0.45; 95% confidence interval (CI): 0.21-0.96; p Canagliflozin therapy at discharge was associated with a lower risk of readmission for HF and a reduction in NT-ProBNP concentration in patients with diabetes after hospitalization for HF. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2077-0383 |
| العلاقة: | http://hdl.handle.net/10668/17094Test; PMC7867051; https://www.mdpi.com/2077-0383/10/3/505/pdf?version=1612164469Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867051/pdfTest |
| DOI: | 10.3390/jcm10030505 |
| الإتاحة: | https://doi.org/10.3390/jcm10030505Test http://hdl.handle.net/10668/17094Test https://www.mdpi.com/2077-0383/10/3/505/pdf?version=1612164469Test https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867051/pdfTest |
| حقوق: | Attribution 4.0 International ; http://creativecommons.org/licenses/by/4.0Test/ ; open access |
| رقم الانضمام: | edsbas.871799DB |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 20770383 |
|---|---|
| DOI: | 10.3390/jcm10030505 |